Latest & greatest articles for olmesartan

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on olmesartan or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on olmesartan and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for olmesartan

1. Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension

Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension 30217371 2018 09 15 1879-1913 2018 Aug 04 The American journal of cardiology Am. J. Cardiol. Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension. S0002-9149(18)31494-2 10.1016/j.amjcard.2018.07.022 Two post hoc analyses in self-identified black and white patients with hypertension evaluated the angiotensin II (...) receptor blocker azilsartan medoxomil (AZL-M) and the fixed-dose combination of AZL-M with chlorthalidone (AZL-M/CLD) versus the ARB olmesartan (OLM) and the OLM fixed-dose combination with hydrochlorothiazide (OLM/HCTZ). One analysis pooled 1,610 patients from two 6-week randomized controlled trials to compare once daily AZL-M 40mg, AZL-M 80mg, OLM 40mg, and placebo. The second analysis included 1,020 patients from a 12-week randomized controlled trial to compare once daily AZL-M/CLD 40/25mg, AZL-M

EvidenceUpdates2018

2. Olmesartan

Olmesartan Top results for olmesartan - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search (...) button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for olmesartan The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory

Trip Latest and Greatest2018

3. Hypertension: avoid olmesartan pending its withdrawal

Hypertension: avoid olmesartan pending its withdrawal Prescrire IN ENGLISH - Spotlight ''Hypertension: avoid olmesartan pending its withdrawal'', 1 May 2016 {1} {1} {1} | | > > > Hypertension: avoid olmesartan pending its withdrawal Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Hypertension: avoid olmesartan pending its withdrawal Olmesartan (...) exposes patients to increased, and sometimes severe, gastrointestinal adverse effects. It is in the best interest of patients not to use it. Olmesartan, commercialised for hypertension, is no more effective than the other sartans or than ACEs (angiotensin-converting enzyme inhibitors) against the cardiovascular complications of hypertension. Since mid-2012, excessive, sometimes severe, gastrointestinal adverse effects (enteropathies) with diarrhoea, sometimes intense abdominal pains, weight loss, etc

Prescrire2016

4. Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study

Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study 26250345 2016 09 09 2016 09 09 1468-3288 65 10 2016 Oct Gut Gut Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study. 1664-9 10.1136/gutjnl-2015-309690 Severe sprue-like enteropathy associated with olmesartan has been reported, but there has been no demonstration of an increased risk by epidemiological studies. To assess (...) , in a nationwide patient cohort, the risk of hospitalisation for intestinal malabsorption associated with olmesartan compared with other angiotensin receptor blockers (ARB) and ACE inhibitors (ACEIs). From the French National Health Insurance claim database, all adult patients initiating ARB or ACEI between 1 January 2007 and 31 December 2012 with no prior hospitalisation for intestinal malabsorption, no serology testing for coeliac disease and no prescription for a gluten-free diet product were included

EvidenceUpdates2015

5. Olmesartan medoxomil / amlodipine besilate / hydrochlorothiazide (Sevikar HCT) - In adult patients whose blood pressure is not adequately controlled on the combination of olmesartan medoxomil and amlodipine taken as dual-component formulation.

Olmesartan medoxomil / amlodipine besilate / hydrochlorothiazide (Sevikar HCT) - In adult patients whose blood pressure is not adequately controlled on the combination of olmesartan medoxomil and amlodipine taken as dual-component formulation.

Scottish Medicines Consortium2012

6. Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis

Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis Wang L, Zhao JW, Liu B, Shi D, Zou Z, Shi XY CRD summary This review found that olmesartan was associated with better antihypertensive efficacy than losartan and valsartan (...) , for patients with hypertension. The adverse events with olmesartan were similar to those with the other angiotensin-receptor blockers. The review was generally well conducted, and the authors' conclusions are likely to be reliable. Authors' objectives To assess the efficacy and tolerability of olmesartan medoxomil, compared with other angiotensin-receptor blockers, in patients with hypertension. Searching PubMed, EMBASE, SinoMed, and Cochrane Central Register of Controlled Trials (CENTRAL) were searched

DARE.2012

7. Olmesartan medoxomil hydrochlorothiazide (Sevikar HCT) - as substitution therapy in adult patients whose blood pressure is adequately controlled

Olmesartan medoxomil hydrochlorothiazide (Sevikar HCT) - as substitution therapy in adult patients whose blood pressure is adequately controlled

Scottish Medicines Consortium2011

8. Choice of angiotensin receptor blocker in moderate hypertension: a UK-based costbenefit comparison of olmesartan- and candesartan-based regimens

Choice of angiotensin receptor blocker in moderate hypertension: a UK-based costbenefit comparison of olmesartan- and candesartan-based regimens Choice of angiotensin receptor blocker in moderate hypertension: a UK-based costbenefit comparison of olmesartan- and candesartan-based regimens Choice of angiotensin receptor blocker in moderate hypertension: a UK-based costbenefit comparison of olmesartan- and candesartan-based regimens Belsey JD Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim of the study was to compare mean costs per patient of target-driven hypertension treatment using olmesartan with the same approach using candesartan in patients with previously untreated moderate hypertension in the UK. The authors

NHS Economic Evaluation Database.2011

9. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.

Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. 21388309 2011 03 10 2011 03 22 2012 11 15 1533-4406 364 10 2011 Mar 10 The New England journal of medicine N. Engl. J. Med. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. 907-17 10.1056/NEJMoa1007994 Microalbuminuria is an early predictor of diabetic nephropathy and premature cardiovascular disease. We investigated whether treatment with an angiotensin-receptor blocker (ARB) would (...) delay or prevent the occurrence of microalbuminuria in patients with type 2 diabetes and normoalbuminuria. In a randomized, double-blind, multicenter, controlled trial, we assigned 4447 patients with type 2 diabetes to receive olmesartan (at a dose of 40 mg once daily) or placebo for a median of 3.2 years. Additional antihypertensive drugs (except angiotensin-converting-enzyme inhibitors or ARBs) were used as needed to lower blood pressure to less than 130/80 mm Hg. The primary outcome was the time

NEJM2011

10. Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis

Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis 20202514 2010 03 05 2010 03 29 2016 11 25 1558-3597 55 10 2010 Mar 09 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten (...) on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial. 976-82 10.1016/j.jacc.2009.09.062 The aim of this study was to evaluate the impact of olmesartan on progression of coronary atherosclerosis. Prior intravascular ultrasound (IVUS) trial results suggest slowing of coronary atheroma progression with some medicines but have not shown convincing evidence of regression with angiotension-II receptor blocking agents. A prospective, randomized, multicenter trial-OLIVUS (Impact

EvidenceUpdates2010

11. Tribenzor (olmesartan medoxomil / amlodipine / hydrochlorothiazide)

Tribenzor (olmesartan medoxomil / amlodipine / hydrochlorothiazide) Drug Approval Package: TRIBENZOR (olmesartan medoxomil and amlodipine) NDA #200175 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - TRIBENZOR (olmesartan medoxomil / amlodipine / hydrochlorothiazide) Tablets Company: Daiichi Sankyo, Inc. Application No.: 200175 Approval Date: 07/23/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634

FDA - Drug Approval Package2010

16. Olmesartan medoxomil (Olmetec)

Olmesartan medoxomil (Olmetec) Secretariat - Delta House 50 West Nile Street Glasgow G1 2NP Telephone 0141 225 6997 Fax 0141 248 3778 E-mail jmitchell@htbs.org.uk Chairman Professor David Lawson Scottish Medicines Consortium Olmesartan Medoxomil (Olmetec Ò ) (No. 78/03) Sankyo Pharma UK Ltd Summary of Recommendation 10 November, 2003 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland (...) . The recommendation is summarised as follows: Advice: following a full submission. Accepted for restricted use within NHS Scotland. Olmesartan has been shown to be at least as effective as other angiotensin II receptor antagonists (AIIAs) for the treatment of hypertension. It may be considered for use, along with other A11As, as an alternative in patients unable to tolerate an ACE inhibitor. Professor David H Lawson Chairman

Scottish Medicines Consortium2003